Indoco Remedies Ltd

Indoco Remedies Limited will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for dealing in equity shares of Indoco Remedies Limited will remain closed for designated persons and their immediate relatives until October 29, 2026.

Indoco Remedies Limited informed the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, has confirmed compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Indoco Remedies Limited announced the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, on September 26, 2026, under the Companies Act, 2013. Warren Lifesciences Private Limited has an authorized share capital of Rs 100,000 divided into 10,000 equity shares of Rs 10 each, and will focus on the manufacture, development, and sale of pharmaceutical products, including active pharmaceutical ingredients and finished formulations. Indoco Remedies will hold 100% of the subsidiary's paid-up share capital through a cash consideration of Rs 10 per share.

Indoco Remedies Limited will close its trading window for equity shares from October 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in accordance with SEBI regulations and company policy.

Indoco Remedies Limited announced that its Committee of Executive Directors has approved the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, for which name approval has been received from the Registrar of Companies, Mumbai. The new company, to be incorporated in India, will operate in the pharmaceutical sector and intends to manufacture, develop, and sell pharmaceutical products including active pharmaceutical ingredients, finished formulations, and key starting materials, with Indoco Remedies Limited holding 100% shareholding and an authorized and paid-up equity share capital of Rs 1,00,000 divided into 10,000 equity shares of Rs 10 each.

Indoco Remedies Limited announced it executed a deed of conveyance on August 27, 2026, to sell a plot of land measuring approximately 2,876.08 square meters to Kalpataru Townships Private Limited for Rs 64,00,00,000. The company stated the sale will not impact its business operations and does not constitute a substantial undertaking, and that no related parties are involved.

Indoco Remedies Limited has fixed Thursday, September 10, 2026, as the record date for determining entitlement to a final dividend of Rs 0.20 per equity share for the financial year ended March 31, 2026, subject to shareholder approval at the Annual General Meeting scheduled for September 17, 2026; the company’s register of members and share transfer books will remain closed from September 11, 2026, to September 17, 2026, and Thursday, September 10, 2026, is also the cut-off date for remote e-voting and e-voting during the AGM.

Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year. The company reported a profit before tax of Rs 77.72 crore in Q1 FY27 compared with a pre-tax loss of Rs 36.66 crore in Q1 FY26. It also recorded exceptional gains of Rs 97.34 crore during the quarter. Aditi Panandikar, managing director, Indoco Remedies, said, 'The first quarter of the financial year 2026-27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient domestic formulation business, while our international formulations and API businesses continued to make steady progress.' Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company's turnover is $175 million with human capital of over 6,000 employees, including over 300 skilled scientists and field staff who are the strength of the organization. Shares of Indoco Remedies fell 5.89% to Rs 233.15 on the BSE.Powered by Capital Market - Live

Net profit of Indoco Remedies reported to Rs 64.99 crore in the quarter ended June 2026 as against net loss of Rs 35.79 crore during the previous quarter ended June 2025. Sales rose 8.21% to Rs 466.22 crore in the quarter ended June 2026 as against Rs 430.86 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales466.22430.86 8 OPM %8.804.07 - PBDT14.91-6.96 LP PBT-19.62-36.66 46 NP64.99-35.79 LP Powered by Capital Market - Live

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 28 July 2026.